-+ 0.00%
-+ 0.00%
-+ 0.00%

AstraZeneca's second-quarter revenue was US$15.38 billion, and its anti-cancer business revenue increased 15% year over year, and is advancing the 2030 revenue target of US$80 billion. The CEO said he is confident in the R&D pipeline. With the launch of new drugs such as Baxfendy and Etcamah, the plan to launch 20 new drugs by 2030 has been more than half completed.

Zhitongcaijing·07/27/2026 13:17:12
Listen to the news
AstraZeneca's second-quarter revenue was US$15.38 billion, and its anti-cancer business revenue increased 15% year over year, and is advancing the 2030 revenue target of US$80 billion. The CEO said he is confident in the R&D pipeline. With the launch of new drugs such as Baxfendy and Etcamah, the plan to launch 20 new drugs by 2030 has been more than half completed.